Introduction
Despite current treatment regimens, patients with glioblastoma (GBM) have a very poor prognosis and new effective treatments are urgently required. The modified herpes simplex virus, HSV1716, has the potential to be a new therapeutic tool.
1,2 HSV1716, a mutant lacking both copies of the RL1 gene that encodes the protein ICP34.5, a specific determinant of virulence, selectively replicates in actively dividing cells but not in terminally differentiated cells. [3] [4] [5] The virus lyses human GBM cells in vitro and in model systems it reduces brain tumours while failing to replicate in normal tissue. 6, 7 We have shown that HSV1716 is safe following injection into normal and tumour-bearing animal brain at innocula X10 6 PFU. 8 This is our third clinical trial using HSV1716 in glioma patients. Our previous trials involved intratumoural injection of HSV1716 at doses up to 10 5 PFU, in patients with high-grade glioma.
1,2 They demonstrated the safety of the virus at this input dose. None of the 21 patients experienced any adverse symptoms attributable to virus administration. Parallel with the publication of our initial study, Markert et al 12 showed that G207, a double mutant derivative of a HSV deleted in both copies of the gamma 34.5 gene in addition to a lacZ insertion disabling the UL39 gene, was safe when injected into patients with malignant glioma at a maximum dose of 3 Â 10 9 PFU. We chose not to escalate the dose of HSV1716 to achieve toxicity. 1 Dose escalation is accepted practice in a conventional phase I study using a nonbiological agent such as chemotherapy. HSV1716 has the potential to replicate in a tumour, and consequently the final titre may be several orders of magnitude higher than the inoculated dose. Extrapolating in vitro data, an input dose of HSV1716 could be amplified 200-fold in 12 h. 9 It has been proposed that phase I trials using biological therapies require new end points when such agents may produce nonspecific and sporadic toxicities, which are not input dose related. 10, 11 HSV1716 is less attenuated than G207, and based on preclinical and clinical data, we remain confident that 10 5 -10 6 PFU HSV1716 should result in clinically relevant tumour cell kill.
Our second trial was a proof of principle study. This involved intratumoural injection of HSV1716 at 10 5 PFU, followed by surgical resection of the lesion between 4 and 9 days in patients with recurrent and newly diagnosed GBM.
2 As well as confirming the safety of HSV1716, this study provided evidence of viral replication. In two HSV seronegative patients, who subsequently seroconverted, infectious virus was recovered from tumour samples taken from the injection site at the time of surgery. In addition, HSV DNA was detected by polymerase chain reaction (PCR) in tumour around the injection site from 10 patients, of whom four had HSV DNA-positive tumour tissue distal to the injection site. The PCR used to detect HSV DNA was unable to distinguish between wild-type HSV and HSV1716. Semiquantitative PCR of tumour tissue provided evidence of virus replication in these seropositive patients, indicating that HSV antibody did not prevent lytic replication of HSV1716. In two patients (one seronegative and one seropositive), immunohistochemical analysis of the resected tumour samples detected HSV antigen at the injection site.
It is envisaged that HSV1716 will be used in combination with standard therapies. One likely application is in patients who have undergone surgical resection, but who have residual tumour that cannot be excised. Following resection there is normally rapid tumour regrowth, and we reasoned that these actively dividing cells could present an ideal environment for replication of HSV1716. In the present study, virus was delivered into the rim of the resection cavity, that is, into the 'brain adjacent to tumour'. This strategy not only allowed the assessment of safety of HSV1716 when injected into the brain adjacent to tumour but also allowed the assessment of the ability of the virus to eliminate any residual tumour. Patients were closely monitored for clinical evidence of toxicity and for evidence of potential therapeutic benefit.
Patients and methods

Inclusion criteria
Of the 12 patients, six with recurrent disease and six newly diagnosed, who were suitable for tumour decompression were included. According to Gene Therapy Advisory Committee advice, the newly diagnosed patients were enrolled after the successful completion of three patients with recurrent disease. Patients with supratentorial tumours amenable to surgical resection and to injection with HSV1716 without the risk of intraventricular injection were entered. Patients had to be between 18 and 70 years of age with a Karnofsky status 460 and no evidence of active acute infection, serious comorbidity or HIV positivity. Patients and relatives were counselled on a number of occasions by clinicians as well as by an independent physician. They were provided with relevant literature and given time to reflect prior to providing their informed consent for participation. The study protocol was approved by the local Ethics Committee, the Gene Therapy Advisory Committee and the Medicines Control Agency for the UK, Department of Health.
Operative procedures and administration of HSV1716
Under general anaesthesia, patients underwent craniotomy. Following confirmation of high-grade glioma on smear preparation, a comprehensive debulking procedure was performed. On completion, 1 ml of 10 5 PFU of HSV1716 was injected into the brain adjacent to tumour. Aliquots of 0.1-0.2 ml of HSV1716 were injected into eight to 10 sites of the brain adjacent to tumour using an insulin syringe. The sites of injection were selected in order to avoid injection into the vascular or ventricular system.
Imaging
Magnetic resonance imaging (MRI) (10 patients) or computed tomography, if MRI was not tolerated (two patients) with and without contrast, was performed preand postoperatively, then two monthly for the first year and thereafter on a six monthly basis. This showed the structural anatomy of the surrounding brain, the glioma and the areas of neovascularity outlined by enhancement related to the most active areas of cell replication. At the same time intervals patients also underwent SPECT (Single Photon Emmision Computed Tomography) with Thallium-201. This is a potassium analogue and identifies areas of high cellular metabolic activity reflecting high-grade tumour growth. Patients underwent imaging outwith protocol when clinically indicated. Images taken at the Institute of Neurological Sciences, Southern General Hospital, Glasgow or any other institution were all reviewed by the study Neuro-radiologist for evidence of tumour progression.
Virus production
GMP-grade HSV1716 was manufactured by Q-One Biotech Ltd, Glasgow, UK. A paired sample of virus was titrated prior to virus administration to the patients. Details have been described in Rampling et al. 
Assays for infectious HSV in blood
Serum samples were analysed as described in Papanastassiou et al.
2
PCR assays for HSV DNA DNA from serum samples was assayed using PCR as detailed in Papanastassiou et al. 2 The PCR was unable to differentiate between wild-type HSV and HSV1716.
Immonoglobulin ELISA assay
ELISA for HSV-1 IgG and IgM was carried out using a Virotech HSV-1 specific kit as described by Rampling et al.
1
HSV replication assay
Tumour samples taken from patients at the time of surgical resection were dissociated and cultured in DMEM with 15% foetal calf serum and antibiotic at 371C and 5% CO 2 . After approximately three passages, Safety data and long-term survival of HSV1716 injection S Harrow et al enough cells were obtained to carry out a multicycle HSV growth experiment. Cells were infected at a multiplicity of infection (MOI) of 0.1 PFU/cell with either HSV1716 or the parental HSV17 + . One plate of cells was mock infected. Following incubation, the samples were harvested at 0, 6, 24, 48 and 72 h after infection. Virus was released by sonication and titrated on BHK cells. Parallel multicycle infections were carried out in BHK cells, which are fully permissive for HSV1716 replication and in 3T6 cells, which are nonpermissive for HSV1716 replication but permissive for wild-type HSV replication. 13 
Clinical assessment
All patients underwent a comprehensive clinical workup with full neurological examination. Immunological (HSV IgG and IgM serology), haematological (full blood count with white cell count differential) and biochemical (urea and electrolytes, liver function tests, bone profile) parameters were recorded (Table 3 ). Prior to the day of surgery each patient was commenced on dexamethasone, 16 milligrams (mg) in four divided doses. Postoperatively, patients were nursed in a single room for 7 days. Twice daily, clinical and neurological parameters were recorded. In particular, patients were monitored for evidence of pyrexia, tachycardia, blood pressure changes, alterations in consciousness (Glasgow Coma Scale), neurological deficit, neck stiffness, photophobia and rash. Haematological, biochemical and serological measurements were taken every 2nd day. Repeat imaging was performed within a week of the procedure. The dose of dexamethasone was reduced postoperatively, with the intention of discontinuing the medication where the clinical condition of the patient permitted. Complete withdrawal of dexamethasone was achieved in 10 patients at different stages within the first few weeks postoperatively. The remaining two patients, 2 and 6, required a maintenance dose of dexamethasone to maintain clinical stability. Dexamethasone was reintroduced following the detection of tumour recurrence when clinically indicated. Following discharge from hospital, patients were seen on a weekly basis for a further 5 weeks to enable clinical, haematological, biochemical and serological assessment. (Details of the serological analysis for HSV-specific IgG and IgM are shown in Figure 1 .) Patients were reimaged 6 weeks postvirus injection and thereafter further assessment and imaging was undertaken every 2 months. In addition, they were regularly assessed clinically by the neuro-oncologist. Of the 12 patients, 11 went on to receive further standard therapy (Table 2) .
Results
Patient profiles
A total of 12 patients (two women and 10 men) were treated within a period of 9 months. Six had previously received treatment for histologically proven glial tumours and six had newly diagnosed disease, assessed as high-grade glioma on imaging. Barthel score and Karnofsky status were within study limits and ranged from 8 to 20 and 60 to 100, respectively. Data on each patient are shown in Table 1 .
Clinical progress
There was no clinical evidence in any patient of toxicity associated with HSV 1716. To date, 22 months since commencing the study and 14 months since the last patient was treated, 10 patients have shown evidence of tumour progression clinically and radiologically. Of the 10, eight have subsequently died due to the progression, one has died from a presumed myocardial infarction and the remaining patient is well following further reresection and a course of chemotherapy at 18 months after virus injection. Patients 1 and 10 are tumour progression free and remain well (Table 2) .
Patient 1 has shown remarkable improvement over the past 22 months with no clinical or radiological evidence of disease progression. Imaging data from this patient are shown in Figure 2 , which illustrates T2-and T1-weighted postcontrast axial MRI of two adjacent sections at four time periods with similar Thallium-201, SPECT sections. The images taken preresection and virus injection (a) shows a large enhancing necrotic left parietal GBM recurrence, surrounded by vasogenic oedema with marked thallium uptake. Images taken 48 h after resection and virus injection (b) show a resection cavity with a moderate enhancing margin containing a fluid level surrounded by vasogenic oedema. No thallium uptake is present on the SPECT images. Follow-up at 6 weeks (c) indicates that the resection cavity has reduced in size with the reduction in mass effect on the adjacent left lateral ventricle. There is minimal marginal enhancement and marked reduction in vasogenic oedema. On the SPECT images there is no thallium uptake. The imaging at 22 months postresection and virus injection (d) shows that the resection cavity is minute, with ex vacuo enlargement of the left lateral ventricle and no marginal enhancement. Once again there is no abnormal thallium uptake on the SPECT images to suggest tumour regrowth. His clinical response is of particular note, given his poor preoperative condition (KS 60:BS 8), the size of his tumour and that following surgical resection and HSV1716 injection he has declined further treatment. Currently, his Karnofsky status is 90 and his Barthel score 18/20. Improved strength on his left side has resulted in increased mobility.
Patient 10 remains tumour progression free at 15 months postresection and HSV1716 injection. Patient 7 showed clinical and radiological signs of progression on completion of radical radiotherapy 12 weeks after surgical resection. He required further debulking surgery and has subsequently received six cycles of CCNU chemotherapy without incident. His disease remains stable at 18 months since HSV1716 injection and 15 months since reresection and chemotherapy. Patient 12 developed evidence of tumour recurrence at 8 months following virus injection. He commenced chemotherapy and received two cycles of Temozolamide. He died at 11 months post-HSV1716 injection from a presumed myocardial infarction.
Some patients experienced adverse events thought to be unconnected with HSV1716 administration (Table 2) . Three events, in particular, merit further discussion.
Patient 1 had a slow recovery period due to his poor preoperative condition. At 78 days after surgery and HSV1716 injection, he suffered a seizure and required ventilation and antiepileptic medication. He had no prior Safety data and long-term survival of HSV1716 injection S Harrow et al history of seizures and was not receiving anticonvulsant medication. The first blood sample after the seizure to be analysed in our laboratory was taken on the 5th day (83) after admission to his local hospital. This sample was positive for HSV DNA on PCR analysis. He recovered well and was discharged from hospital on a maintenance dose of Phenytoin and has had no subsequent adverse events.
At 6 week following surgery, patient 3 was clinically reviewed, and it was noted that he had discontinued his oral steroid medication contrary to medical advice. Clinical examination revealed that his craniotomy wound was swollen and felt boggy on palpation. He had reduced power in his right arm and leg and there was evidence of papilloedema on fundoscopy. Imaging indicated the presence of a CSF meningocoele. A lumboperitoneal shunt was inserted that was later replaced with a ventriculoperitoneal shunt, and he clinically improved. This is a recognised complication in patients who undergo repeated craniotomy for tumour recurrence and was not related to the administration of HSV1716 into the resection cavity rim.
At 2 months after virus injection and shortly after completing a standard course of radiotherapy, patient 5 suffered a complex partial seizure and was commenced on Carbamazepine. He was subsequently readmitted with pyrexia of unknown origin and a generalised rash. Clinical assessment and laboratory investigations failed to confirm a diagnosis. No HSV DNA was found in the blood and cerebrospinal fluid samples by PCR analysis (this test being sensitive at levels equivalent to10 2 PFU/ ml). Although there was no evidence that HSV1716 was implicated, acyclovir was administered as a precautionary measure as he continued to deteriorate despite broad-spectrum antibiotics and supportive treatment. Despite the acyclovir, he remained unwell with a spiking temperature. At 2 weeks following hospital admission, a positive platelia monoclonal antibody ELISA test for Candida antigen confirmed invasive candidosis. He was treated with intravenous Fluconazole. His temperature settled and clinical improvement became apparent.
Patient 12, a poorly controlled type II diabetic with resulting secondary complications had consistently elevated blood sugar recordings postoperatively. To achieve adequate control he required subcutaneous insulin. Within a month of discharge he was readmitted with a Varicella zoster rash in a bilateral C5/6 distribution, but no intervention was warranted. No evidence of HSV was obtained by PCR or virus shedding assays on numerous serological and vesicular fluid samples.
Laboratory data
Prior to the injection of HSV1716, it was noted that each patient demonstrated abnormalities in their immune systems as indicated in Table 3 . After each appointment at the clinic, patient serum samples were analysed for routine biochemistry and haematology. No unexpected results or trends, for a cohort such as this, were detected. In addition, blood samples were analysed in our laboratory for infectious HSV; HSV DNA by PCR and for HSV-1 IgG and IgM by ELISA. Figure 1 shows the IgG and IgM responses for each patient throughout the clinical trial. Patients 2, 3 and 4 were HSV seronegative at the time of enrolment. Of these, patients 3 and 4 mounted an immune response and seroconverted between the 3rd and 4th week postvirus injection. At this point neither patient was receiving immunosuppressive dexamethasone medication. Patient 3 showed evidence of disease progression at 10 months following injection of HSV1716 and died at 11 months. Patient 4 also died at 11 months after virus injection. The remaining patient (2) did not mount an immune response and died 6 months after the injection of virus. Unlike the other two patients, he remained on high-dose steroids to maintain clinical well-being. The continued administration of immunosuppressive dexamethasone may explain why he failed to generate an appropriate immune response.
Serum samples from four patients have been positive for HSV DNA. Of these, patients 1, 5 and 10 were seropositive, and had a prior clinical history of HSV infection (cold sores). They were PCR positive some time after the injection of HSV1716. At present, our PCR assay fails to distinguish endogenous HSV1 from HSV1716. Although unlikely, it cannot be ruled out that the HSV DNA detected in these patients could be the result of a subclinical viraemia associated with the reactivation of endogenous latent HSV1. Patient 3 was seronegative Safety data and long-term survival of HSV1716 injection S Harrow et al prior to the injection of HSV1716 and seroconverted at day 24, the same time at which HSV DNA was detected in his serum.
HSV replication assay in patient tumour samples
Tumour tissue was taken from each patient at the time of his or her initial surgery and cells from the tissue were 
Discussion
In this study, HSV1716 was injected into the tissue involving functioning brain, which surrounded the cavity following resection of high-grade glioma in patients who were intrinsically and iatrogenically immunocompromised. None of the 12 patients demonstrated clinical evidence of toxicity associated with HSV1716. The study has demonstrated the safety of HSV1716 following injection into the brain adjacent to tumour. Given that HSV is both neurotropic and neurovirulent, the demonstration that HSV1716 is avirulent when injected into the brain adjacent to tumour has considerably strengthened its safety profile.
The expected median survival in patients with GBM is approximately 1 year from diagnosis (with 10% surviving 2 years) and 3-6 months following recurrence.
14 To date in this trial, three patients with GBM are alive. Of the six patients with recurrent disease, patient 1 remains alive and well at 22 months since surgery and HSV1716 injection with no radiological evidence of disease recurrence. Among the newly diagnosed cohort, two patients (7 and 10) are alive at 18 and 15 months, respectively.
The clinical progress of the first patient warrants discussion. He was initially diagnosed at another institution following a stereotactic biopsy and received two cycles of neoadjuvant chemotherapy, Temozolamide, prior to standard radiotherapy of 60 Gy in 30 fractions. Despite being on high-dose steroids, there was clinical deterioration within 6 months, as well as imaging evidence of tumour regrowth. On entry into the study, this patient had a large left parieto-occipital tumour with resultant mild right hemiparesis and was grossly cushingoid. He was the most disabled of the patients with the lowest Karnofsky (60) and Barthel (eight) indices. Following surgery and HSV1716 administration, he has declined standard chemotherapy and has received no further intervention up to 2 years later. He has improved strength on the right-hand side and his mobility has improved. Nearly 3 months post-HSV1716 administration, HSV DNA was detected by PCR in a blood sample taken 5 days following admission to hospital due to seizure activity. There was no accompanying rise in HSV-specific IgM or IgG. We cannot, however, conclude an association between the onset of seizure activity and the detection of HSV DNA in his serum. Owing to the limitations of our PCR assay, we are unable to distinguish between wild-type HSV and HSV1716. We are currently developing a PCR assay to distinguish HSV1716 from wild-type HSV. This has proved extremely difficult as the DNA adjacent to the genomic deletion in HSV1716 is highly GC rich (480%) and contains numerous repeat sequences. Patient 1's clinical improvement and disease-free survival coupled with the imaging data are of interest given that he has not received adjuvant treatment. Imaging indicates that there has been tumour regression over the duration of the study, most evident in the recent imaging (Figure 2) . He has remained seizure free since the aforementioned episode and has continued to reduce the dose of Phenytoin with no adverse events. He no longer requires steroids. A causal relationship between his continued well-being and the procedure cannot be established and we fully accept that this study was not designed to test for efficacy. At 22 months postprocedure and 29 months from initial diagnosis, he remains in complete clinical and radiological remission.
The design of this study was based on the rationale that resection followed by virus injection into the cavity rim may be an appropriate way in which to deliver HSV1716 in routine clinical practice. Conventional radio- Safety data and long-term survival of HSV1716 injection S Harrow et al therapy and/or chemotherapy would follow at a later stage. As the majority of patients with high-grade glioma show disease recurrence up to 2 cm from the site of the original tumour, it was hypothesised that lytic replication of virus in residual tumour might control regrowth. In this cohort of patients, there has been considerable variation in disease progression times. A maximum of 10 injection points were used to deliver the virus into the large surface area of a resection cavity. It would not be surprising if HSV1716 in some instances failed to come into contact with tumour cells and to generate a productive lytic infection. In retrospect, the nature of a resection cavity, with the associated inflammation at the time of surgery, may not be the ideal environment in which to inject virus. Virus injection several days postsurgery would be preferred from the point of view of maximising the ability of HSV1716 to replicate but would involve two intervention procedures with resultant risks.
We are satisfied with the outcome of this trial in terms of safety and in the overall patient response, but it is clear from this and other trials using selectively replication-competent viruses that optimisation of virus delivery procedures needs to be explored as a priority.
We cultured cells from four tumour samples taken at the time of surgical resection and assessed their permissivity for HSV1716 replication. We demonstrated that the tumour cells obtained from the primary tumour were permissive to HSV1716 replication (Figure 3) .
Obviously, the environment within the brain following resection of high-grade glioma is associated with additional features, such as immune system responses, which may impair the replication of HSV1716. These results, however, confirm that in optimum conditions HSV1716 has the ability to replicate in high-grade glioma cells.
This study demonstrates conclusively that HSV1716 can be injected into the normal brain in immunocompromised individuals with no concomitant clinical toxicity. The clinical results obtained from the three phase I studies have been encouraging and warrant further investigation. Currently, we are developing plans to proceed with an efficacy trial in glioma patients.
